Navigation Links
Why African-Americans are at greater risk of hypertension and kidney disease
Date:7/13/2009

NEW YORK (July 13, 2009) -- Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center believe that a heightened level a certain growth factor in the blood may explain why blacks have a greater prevalence of hypertension and kidney disease compared to whites. Results from a new study are the first to show that an elevated level of a protein, called transforming growth factor B1 (TGF-B1), raises the risk of hypertension and renal disease in humans.

African Americans constitute about 32 percent of all patients treated for kidney failure in the U.S. and are four times more likely to develop renal disease than whites, according to the National Institutes of Health's U.S. Renal Data System. The researchers' findings, published in this month's issue of the journal Kidney International, may someday lead to the development of a new class of anti-hypertensive and kidney disease drugs that target the TGF-B1 protein.

"I believe we may now understand a great puzzle: why the black population has a greater prevalence of hypertension and kidney disease," says Dr. Manikkam Suthanthiran, first author of the study and attending physician at NewYork-Presbyterian/Weill Cornell, Stanton Griffis Distinguished Professor of Medicine, Professor of Biochemistry and Professor of Medicine in Surgery at Weill Cornell Medical College.

Results from the study revealed that the TGF-B1 protein was significantly higher in 186 black study participants compared with 147 white participants.

After controlling for race, sex and age, TGF-B1 protein levels were highest in hypertensive blacks (46 ng/ml). Non-hypertensive blacks also had higher levels (42 ng/ml) compared to hypertensive whites (40 ng/ml) and non-hypertensive whites (39 ng/ml), demonstrating that even healthy black patients may be at higher risk for future hypertension and renal disease compared to healthy and hypertensive whites.

"Many black patients may have a disadvantage from the start -- having a higher baseline level of TGF-B1," says Dr. Phyllis August, senior author and attending physician in the division of hypertension at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Ralph A. Baer Professor of Medical Research and professor of medicine atWeill Cornell Medical College.

While the exact mechanisms of TGF-B1 require further study, the authors believe that in black patients, higher levels of the growth factor are correlated with lower renin activity -- an enzyme that constricts blood vessels and raises blood pressure. High blood pressure is the leading risk factor for end-stage kidney disease.

The authors believe it may be possible that higher levels of TGF-B1 boost retention of sodium salt within the kidneys, leading to higher blood pressure in the kidney and also lower levels of renin.

Greater levels of TGF-B1 in blacks were also positively associated with body mass index (BMI) -- indicator of body fatness compared to height -- and metabolic syndrome -- a group of abnormalities that is associated with atherosclerotic vascular disease and diabetes.

"Future clinical studies must be done so we may fully understand the specific role of TGF-1 in how the kidney handles sodium, blood pressure and kidney disease." Says Dr. August.


'/>"/>

Contact: Limda Kamateh
lib9027@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. What is different in reflux esophagitis between African-Americans and non-Hispanic whites?
2. Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes
3. Hormone linked to high blood pressure and blood vessel disease in African-Americans
4. Childrens Hospital study finds African-Americans more distrusting of research than whites
5. African-Americans have worse prognosis at colorectal cancer diagnosis
6. Fear, misconceptions about screenings keep many African-Americans from getting mammograms
7. MYH9 gene variations help explain high rate of kidney disease in African-Americans
8. American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes
9. Newly found gene variants account for kidney diseases among African-Americans
10. Kidney disease worsens in a fourth of African-Americans despite therapy for hypertension
11. New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the ... use of health IT to create efficiencies in healthcare information exchange and a trusted ... 2017 Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head ...
(Date:8/23/2017)... Ogden, Utah (PRWEB) , ... August 23, 2017 , ... ... 2013. , Give Back Day is a time Nightingale College dedicates to serving ... with organizations that thrive on donations and volunteers or those that need a little ...
(Date:8/23/2017)... ... August 23, 2017 , ... Boling Vision ... home to Indiana, and is now seeing patients at Boling Vision Center’s Elkhart ... in the diagnosis and treatment of eye disease, medical retina, high-technology cataract surgery, ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC Advantage ... - for Risk Management Solution Innovations and Security Solution for Government Innovations. Both ... in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , The ...
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing ... Relief with the 2017 Women’s Choice Award. The identification by women of an ... of 4 migraine sufferers are women. In a survey taken by the Women’s Choice ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: